羥乙基淀粉治療分水嶺腦梗死臨床療效研究
[Abstract]:Objective to study the therapeutic effect of dilatation drug hydroxyethyl starch (HES) on watershed cerebral infarction (CWI) in patients with cerebral infarction, and to analyze the difference of clinical efficacy of HES in patients with different types of CWI and the relationship between different types of CWI and intracranial and extracranial vascular stenosis. To find the basis for individualized treatment in clinical work. Methods 93 patients with CWI were selected from October 2010 to May 2016. All the subjects met the diagnostic criteria of cerebrovascular disease of the 4th Symposium on Cerebrovascular Disease. The patients in the group were diagnosed as CWI within 24 hours after the onset of the disease by conventional craniocerebral magnetic resonance (MRI) combined with diffusion weighted imaging (DWI), and there were clinical symptoms and signs related to the infarct foci. Patients with primary onset and previous history of cerebral infarction without significant neurological damage were excluded from systemic hypoperfusion, cardiogenic embolism, autoimmune related diseases, cerebral hemorrhage, tumors and hypersensitivity to hydroxyethyl starch. All the patients were examined by color Doppler ultrasonography and 3 D TOF angiography (MRA) of internal carotid artery extracranial segment. 93 patients with watershed cerebral infarction were randomly divided into two groups: the experimental group (n = 50) and the control group (n = 43). The patients in the experimental group were treated with anti-platelet and cerebral cell protection, and the patients in the control group were given the general treatment of 6% of hydroxyethyl starch injection (130 / 0.4 500ml ivdrip qdx14 / d). NIHSS score was used to assess the degree of neurological impairment at admission, on day 7 and day 14. Result 1. Age, sex, CWI type, hypertension, coronary heart disease, diabetes, hyperlipidemia, smoking history, drinking history were not statistically significant (P0.05). There was no significant difference in NIHSS scores between the two groups on admission (P0.05). On the 7th day and 14th day of treatment, the NIHSS scores of the two groups were significantly improved compared with the admission time (P0.05), at the same time, there was no significant difference between the two groups (P0.05). There was significant difference between the experimental group and the control group in the same period (P0.05). There was significant difference between the two groups on the 7th day and the 14th day (P0.05). There was significant difference in the recovery of nerve function between the two types of CWI patients in the trial group (P0.05). The effect of), HES expansion on subcortical watershed cerebral infarction (IWSI) was better than that of cortical watershed cerebral infarction (CWSI). 3. The positive rate of stenosis in different types of CWI lesions was different. CWSI was associated with ipsilateral (ICA) stenosis of the internal carotid artery (OR = 0.019 鹵95 CI = 0.003 鹵0.227). IWSI was associated with ipsilateral (MCA) stenosis of the middle cerebral artery (OR = 39.271, 95 CI = 3.179, 399.818, P = 0.021). Conclusion 1.HES dilatation is effective in the treatment of CWI, and the symptoms of nerve function impairment are improved. HES dilatation is superior to CWSI.2. in the recovery of IWSI nerve function. There was an important relationship between extracranial and extracranial macrovascular lesions and CWI, and the incidence of ICA,MCA in the lesion side was different according to the type of CWI. CWSI was associated with ICA stenosis on the lesion side and IWSI with MCA stenosis on the lesion side.
【學位授予單位】:青島大學
【學位級別】:碩士
【學位授予年份】:2017
【分類號】:R743.3
【參考文獻】
相關期刊論文 前10條
1 舒豪;聶志余;;腦分水嶺梗死急性期血壓與預后相關性研究[J];中國卒中雜志;2015年09期
2 董美學;胡玲;黃遠軍;賀維;王嘯;魏有東;李琦;謝鵬;;中國人腦分水嶺梗死相關危險因素及其發(fā)病機制分析[J];中風與神經疾病雜志;2014年06期
3 梁峰;胡大一;沈珠軍;;2014美國糖尿病指南:糖尿病診療標準[J];中華臨床醫(yī)師雜志(電子版);2014年06期
4 姜玉龍;吳衛(wèi)文;姜建東;陳皆春;馮壽琴;施鳳菁;;內分水嶺腦梗死擴容治療的臨床研究[J];中國神經免疫學和神經病學雜志;2013年05期
5 崔麗娟;范愛華;鄧小勇;;阿托伐他汀鈣聯合羥乙基淀粉針治療分水嶺腦梗死臨床療效研究[J];臨床醫(yī)學工程;2013年05期
6 馬召璽;王萬華;王紅洲;陸麗蕓;曹勇軍;趙合慶;;伴顱內外動脈狹窄或閉塞的分水嶺腦梗死類型分析[J];臨床神經病學雜志;2012年04期
7 高翔;隋雪琴;趙仁亮;;分水嶺腦梗死與腦血管狹窄[J];國際腦血管病雜志;2012年08期
8 陳燕;駱喜寶;潘云;;羥乙基淀粉的藥理作用和臨床應用研究進展[J];醫(yī)學綜述;2012年04期
9 張麗雅;周旭峰;高志翔;盧超;劉曉萍;;MRA對腦梗塞患者顱內動脈硬化程度評估探討[J];中國CT和MRI雜志;2009年05期
10 朱娟;徐建國;郭曲練;張明生;;比較不同分子量羥乙基淀粉對術中血液循環(huán)及凝血功能的影響[J];臨床麻醉學雜志;2008年11期
,本文編號:2369841
本文鏈接:http://sikaile.net/yixuelunwen/shenjingyixue/2369841.html